Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Die Gynäkologie
Erschienen in: Der Gynäkologe 4/2005

01.04.2005 | Zum Thema

Hormonelle Therapie des polyzystischen Ovarsyndroms (PLOS)

verfasst von: Dr. A. N. Schüring, L. Kiesel

Erschienen in: Die Gynäkologie | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur endokrinen Therapie des heterogenen polyzystischen Ovarsyndroms (PCOS) stehen verschiedene Strategien zur Verfügung, die individuell auf die Patientin abgestimmt werden. Sind hyperandrogenämische Symptome wie Akne und Hirsutismus zu behandeln, wird antiandrogen therapiert und ein Zyklus etabliert. Orale Kontrazeptiva mit antiandrogenen Gestagenen sind dazu Mittel der ersten Wahl, in schwereren Fällen werden zusätzlich höher dosierte Gestagene eingesetzt. Bei Kinderwunsch erfolgt eine ovarielle Stimulation, ideal mit niedrig dosiertem FSH. Die Risiken einer ovariellen Überstimulation und höhergeradigen Mehrlingsschwangerschaft sind zu beachten. Zur Behandlung einer Insulinresistenz können Insulinsensitizer eingesetzt werden. Sie führen in einem großen Anteil der Patientinnen zu Ovulationen, durch Kombination mit einer ovariellen Stimulation lässt sich dieser Effekt noch weiter verbessern.
Literatur
1.
Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333: 853–861
2.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19–25
3.
Geisthövel F (2003) A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome. Reprod Biomed Online 7: 602–605
4.
Legro RS, Strauss JF (2002) Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002 78: 569–576
5.
Schüring AN, Gromoll J, Sonntag B, Nieschlag E, Kiesel L, Greb RR (2004) A polymorphism in the androgen receptor gene (CAG repeats) is associated with polycystic ovary syndrome (PCOS). 60th annual ASRM-meeting, Philadelphia, USA
6.
Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774–800CrossRefPubMed
7.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174PubMed
8.
Burghen GA, Givens JR, Kitabchi AE (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50: 113–116
9.
Cattrall FR, Healy DL (2004) Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 185: 803–812
10.
Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24: 302–312
11.
Balen A (2001) Polycystic ovary syndrome and cancer. Hum Reprod Update 7: 522–525
12.
Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361: 1810–1812
13.
Farquhar C, Vandekerckhove P, Lilford R (2001) Laparoscopic „drilling“ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 4: CD001122
14.
Azziz R (2003) The evaluation and management of hirsutism. Obstet Gynecol 101: 995–1007
15.
Van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R (2002) The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69 [Suppl]: 2–15
16.
Raudrant D, Rabe T (2003) Progestogens with antiandrogenic properties. Drugs 63: 463–492
17.
Venturoli S, Marescalchi O, Colombo FM et al. (1999) A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84: 1304–1310
18.
Falsetti L, Gambera A, Platto C, Legrenzi L (2000) Management of hirsutism. Am J Clin Dermatol 1: 89–99
19.
Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO (1998) Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13: 2706–2711
20.
Van der Spuy ZM, le Roux PA (2003) Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 4: CD001125
21.
Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89: 2817–2823
22.
Shulman LP (2002) Safety and efficacy of a new oral contraceptive containing drospirenone. J Reprod Med 47 [Suppl]: 981–984
23.
Farquhar C, Lee O, Toomath R, Jepson R (2003) Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 4: CD000194
24.
Shaw JC (2000) Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 43: 498–502
25.
Moghetti P, Tosi F, Tosti A et al. (2000) Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85: 89–94
26.
Kelestimur F, Sahin Y (1998) Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril 69: 66–69
27.
Muderris II, Bayram F, Guven M (2000) A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride(5 mg/d) in the treatment of hirsutism. Fertil Steril 73: 984–987
28.
Muderris II, Bayram F, Guven M (2000) Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14: 38–41
29.
Ibanez L, Potau N, Marcos MV, de Zegher F (2000) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85: 3251–3255
30.
Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR (1983) Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol 146: 602–606
31.
Carmina E, Rosato F, Janni A (1986) Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients. J Endocrinol Invest 9: 5–9
32.
Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR (1999) Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab 84: 946–950
33.
Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH (1984) A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 41: 844–848
34.
Bider D, Blankstein J, Levron J, Tur-Kaspa I (1997) Gonadotropins and glucocorticoid therapy for „low responders“ — a controlled study. J Assist Reprod Genet 14: 328–331
35.
Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, Lobo RA (1997) Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 12: 905–909
36.
Acien P, Mauri M, Gutierrez M (1997) Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms. Hum Reprod 12: 423–429
37.
Lemay A, Faure N (1994) Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab 79: 1716–1722
38.
Azziz R, Ochoa TM, Bradley EL, Potter HD, Boots LR (1995) Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab 80: 3406–3411
39.
Hughes E, Collins J, Vandekerckhove P (2000) Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2: CD000087
40.
Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R (2000) Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 4: CD000410
41.
Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R (2002) The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 8: 279–290
42.
Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV (1995) Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10: 1974–1981
43.
Elkind-Hirsch KE, Webster BW, Brown CP, Vernon MW (2003) Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 79: 603–607
44.
Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P (2003) Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online 7: 313–318
45.
Hwang JL, Seow KM, Lin YH et al. (2004) Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 19: 1993–2000
46.
Ludwig M, Felberbaum RE, Devroey P et al. (2000) Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 264: 29–32
47.
Cardone VS (2003) GnRH antagonists for treatment of polycystic ovarian syndrome. Fertil Steril 80 [Suppl]: S25–31
48.
The ESHRE Capri Workshop (1997) Female infertility: treatment options for complicated cases. Hum Reprod 12: 1191–1196
49.
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC (2002) A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 77: 91–97
50.
Thompson LA, Barratt CL, Thornton SJ, Bolton AE, Cooke ID (1993) The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the periovulatory period. Fertil Steril 59: 125–129
51.
Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME (1989) The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol 73: 187–190
52.
Gonen Y, Casper RF (1990) Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 5: 670–674
53.
Shoham Z, Borenstein R, Lunenfeld B, Pariente C (1990) Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf) 33: 271–278
54.
Kousta E, White DM, Franks S (1997) Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 3: 359–365
55.
Gysler M, March CM, Mishell DR, Bailey EJ (1982) A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 37: 161–167
56.
Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC (1998) Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 83: 2361–2365
57.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338: 1876–1880
58.
Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75: 310–315
59.
George SS, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri MS (2003) Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 18: 299–304
60.
Sahin Y, Yirmibes U, Kelestimur F, Aygen E (2004) The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 113: 214–220
61.
Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW (2003) Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79: 562–566
62.
Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J (1998) Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 83: 423–426
63.
Homburg R, Howles CM (1999) Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 5: 493–499
64.
Van Santbrink EJ, Fauser BC (1997) Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 82: 3597–3602
65.
Balasch J, Fabregues F, Creus M, Puerto B, Penarrubia J, Vanrell JA (2001) Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 16: 652–656
66.
Strowitzki T, Seehaus D, Korell M, Hepp H (1994) Low-dose follicle stimulating hormone for ovulation induction in polycystic ovary syndrome. J Reprod Med 39: 499–503
67.
Tadokoro N, Vollenhoven B, Clark S, Baker G, Kovacs G, Burger H, Healy D (1997) Cumulative pregnancy rates in couples with anovulatory infertility compared with unexplained infertility in an ovulation induction program. Hum Reprod 12: 1939–1944
68.
Christin-Maitre S, Hugues JN; Recombinant FSH Study Group (2003) A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 18: 1626–1631
69.
Hughes JN, Cedrin-Durnerin I, Avril C, Bulwa S, Herve F, Uzan M (1996) Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Hum Reprod 11: 2581–2584
70.
Mitwally MF, Casper RF (2002) Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 14: 255–263
71.
Mitwally MF, Casper RF (2002) Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 77: 776–780CrossRefPubMed
72.
Mitwally MF, Biljan MM, Casper RF (2005) Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 192: 381–386
73.
Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ (2002) Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 77: 209–215
74.
Lord JM, Flight IH, Norman RJ (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3: CD003053
75.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338: 1876–1880
76.
Pasquali R, Gambineri A, Biscotti D et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85: 2767–2774
77.
Kocak M, Caliskan E, Simsir C, Haberal A (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 77: 101–106
78.
Stadtmauer LA, Toma SK, Riehl RM, Talbert LM (2001) Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 75: 505–509
79.
Stadtmauer LA, Wong BC, Oehninger S (2002) Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome — beyond ovulation induction. Hum Reprod 17: 3016–3026
80.
Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M (2005) Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed online 10: 100–104
81.
Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73: 1149–1154
82.
Kelly CJ, Gordon D (2002) The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 147: 217–221
83.
Leidenberger FA, Strowitzki T, Ortmann O (2005) Klinische Endokrinologie für Frauenärzte, 3. Aufl. Springer, Berlin Heidelberg New York
84.
Berson DS, Chalker DK, Harper JC, Leyden JJ, Shalita AR, Webster GF (2003) Current concepts in the treatment of acne: report from a clinical roundtable. Cutis 72 [Suppl]: 5–13
85.
Felberbaum RE, Ludwig M, Diedrich K (2000) Clinical application of GnRH-antagonists. Mol Cell Endocrinol 166: 9–14
86.
Keck C, Neulen J, Breckwoldt M (1994) Ovarian hyperstimulation syndrome. Geburtshilfe Frauenheilkd 54: 315–320
87.
Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF (1994) The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. N Engl J Med 331: 244–249
Metadaten
Titel
Hormonelle Therapie des polyzystischen Ovarsyndroms (PLOS)
verfasst von
Dr. A. N. Schüring
L. Kiesel
Publikationsdatum
01.04.2005
Verlag
Springer-Verlag
Erschienen in
Die Gynäkologie / Ausgabe 4/2005
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-005-1673-5

Weitere Artikel der Ausgabe 4/2005

Der Gynäkologe 4/2005 Zur Ausgabe

Weiterbildung · Zertifizierte Fortbildung

Krebsfrüherkennung bei Frauen

Zum Thema

Störungen der Schilddrüsenfunktion

Zum Thema

Update zur Hyperprolaktinämie

Zum Thema

Endokrinologische Diagnostik bei Infertilität

Zum Thema

Aromataseinhibitoren zur Therapie der Endometriose?

Für Sie gelesen

Behandlung intrakavitärer Myome

Neu im Fachgebiet Gynäkologie und Geburtshilfe

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen